Callio Therapeutics

Multi-payload antibody-drug conjugates

Seattle, United States · Founded 2025 · $187.0M raised

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$187.0M
Last Round
$187.0M Series AMar 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Callio Therapeutics is a clinical-stage biotechnology company developing next-generation multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Founded in 2025 and headquartered in Seattle and Singapore, the company's lead program CLIO-8221 is a dual-payload ADC targeting HER2-expressing solid tumors that delivers a topoisomerase 1 inhibitor and an ATR inhibitor simultaneously to overcome resistance to existing ADC therapies.

Summary

Callio Therapeutics is a Biotech company based in Seattle, United States, founded in 2025. It has raised $187.0M in total across 1 round, most recently a $187.0M Series A round in Mar 2025.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2025
$187.0M

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Callio Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/callio-therapeutics"><img src="https://indexed.vc/api/badge/company/callio-therapeutics" alt="Callio Therapeutics on Indexed.vc" width="260" height="76" /></a>